本帖最后由 老马 于 2013-3-13 13:43 编辑 ! l) R) u5 O# C8 x6 I' n
# f4 J1 \3 h, t% N4 J. T
健择（吉西他滨）+顺铂+阿瓦斯汀/ D6 c% r! X, d6 s' o5 I1 t! Y
Gemzar +Cisplatin + Avastin
5 L( w* z" \; B" R' ?8 `0 l* w* N0 {http://annonc.oxfordjournals.org/content/21/9/1804.full
3 i" I* n; s* ~/ g+ @- A3 TOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) X% c. f4 c0 z5 I4 a
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. & P# s+ z0 m2 K7 k4 [# Q0 n
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
* S- ?+ `( M. |$ Z( F7 }$ \1 g5 l
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 625)
* ^# l% c# G5 K6 ~华为网盘附件：/ {/ a4 i6 { K/ \! }4 H) I
【华为网盘】ava.JPG
7 [$ g7 v( k. B' d- P8 r+ ] |
显身卡
